TRAW
Traws Pharma Inc
$
1.520
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.570
Open
1.530
VWAP
1.50
Vol
20.28K
Mkt Cap
8.46M
Low
1.485
Amount
30.41K
EV/EBITDA(TTM)
--
Total Shares
5.56M
EV
-7.42M
EV/OCF(TTM)
--
P/S(TTM)
20.67
Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q4
FY2025Q1
FY2025Q2
60.00K
+7.14%
--
--
60.00K
+7.14%
--
--
60.00K
+5.26%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Traws Pharma, Inc. (TRAW) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 2.01%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+2.01%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for Traws Pharma Inc (TRAW.O) is -0.04, compared to its 5-year average forward P/E of -12.75. For a more detailed relative valuation and DCF analysis to assess Traws Pharma Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-12.75
Current PE
-0.04
Overvalued PE
35.63
Undervalued PE
-61.14
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-0.85
Current EV/EBITDA
0.27
Overvalued EV/EBITDA
2.28
Undervalued EV/EBITDA
-3.97
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
190.99
Current PS
35.32
Overvalued PS
467.53
Undervalued PS
-85.56
Financials
Annual
Quarterly
FY2025Q1
YoY :
+1.79%
57.00K
Total Revenue
FY2025Q1
YoY :
-0.17%
-5.20M
Operating Profit
FY2025Q1
YoY :
-531.27%
21.49M
Net Income after Tax
FY2025Q1
YoY :
-135.30%
2.09
EPS - Diluted
FY2025Q1
N/A
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
YoY :
-523.70%
37.70K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
357.6K
Volume
Months
6-9
2
239.2K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
TRAW News & Events
Events Timeline
2025-06-30 (ET)
2025-06-30
06:34:58
Traws Pharma announced multiple regulatory submissions
2025-06-03 (ET)
2025-06-03
07:02:33
Traws Pharma publishes key efficacy data for rigosertib
2025-05-27 (ET)
2025-05-27
08:08:28
Traws Pharma announces receipt of FDA guidance on tivoxavir marboxil
Sign Up For More Events
Sign Up For More Events
News
9.0
06-30NewsfilterTraws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions
9.0
06-30NASDAQ.COMTraws Pharma Submits Phase 2 Protocols for Tivoxavir Marboxil and Ratutrelvir to HREC and FDA
9.0
06-30SeekingAlphaTraws Pharma advances antiviral pipeline with multiple regulatory submissions
Sign Up For More News
People Also Watch
PULM
Pulmatrix Inc
5.310
USD
-3.10%
IHT
InnSuites Hospitality Trust
1.920
USD
-3.95%
CETY
Clean Energy Technologies Inc
0.285
USD
+14.01%
GLXG
Galaxy Payroll Group Ltd
0.585
USD
0.00%
RCON
Recon Technology Ltd
2.810
USD
-6.33%
KAPA
Kairos Pharma Ltd
0.973
USD
-0.71%
NXTC
NextCure Inc
5.160
USD
-0.77%
FEDU
Four Seasons Education (Cayman) Inc
14.370
USD
0.00%
DATS
DatChat Inc
2.390
USD
-0.83%
FAQ
What is Traws Pharma Inc (TRAW) stock price today?
The current price of TRAW is 1.52 USD — it has decreased -0.65 % in the last trading day.
What is Traws Pharma Inc (TRAW)'s business?
What is the price predicton of TRAW Stock?
What is Traws Pharma Inc (TRAW)'s revenue for the last quarter?
What is Traws Pharma Inc (TRAW)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Traws Pharma Inc (TRAW)'s fundamentals?
How many employees does Traws Pharma Inc (TRAW). have?